Squarepoint’s Idexx Laboratories IDXX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-5,000
Closed -$3.19M 4540
2025
Q3
$3.19M Buy
5,000
+3,100
+163% +$1.88M ﹤0.01% 1739
2025
Q2
$1.02M Buy
+1,900
New +$909K ﹤0.01% 2639
2024
Q3
Sell
-800
Closed -$390K 4359
2024
Q2
$390K Sell
800
-1,400
-64% -$703K ﹤0.01% 3255
2024
Q1
$1.19M Buy
+2,200
New +$1.2M ﹤0.01% 2468

Other funds holding IDXX

Squarepoint's IDXX Position: Q1 2026 in Review

Squarepoint increased its Idexx Laboratories (IDXX) stake by 75% in Q1 2026, buying an estimated $27.5M and bringing the position to 100,309 shares worth $56.4M. The position accounts for 0.07% of the portfolio, ranked #301.

Squarepoint first reported a position in IDXX in Q1 2015 and has held it in 34 quarters since. The position peaked at $92.6M in Q2 2025. 1,311 funds tracked by Wall St. Rank hold IDXX as of Q1 2026.

  • Squarepoint held 100,309 shares of Idexx Laboratories worth $56.4M as of Q1 2026.
  • Squarepoint bought 42,885 Idexx Laboratories shares in Q1 2026, an estimated $27.5M.
  • Idexx Laboratories made up 0.07% of Squarepoint's portfolio in Q1 2026, its #301 holding.
  • Squarepoint first reported a position in Idexx Laboratories in Q1 2015 and has held it in 34 quarters since.
  • Squarepoint's Idexx Laboratories position peaked at $92.6M in Q2 2025.
  • 1,311 funds tracked by Wall St. Rank held Idexx Laboratories as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.